Curative effect of Naoxintong Capsules combining metoprolol on coronary heart disease complicating frequent premature ventricular contraction

SHAO Ling; XIONG Tao

doi:10.3969/j.1674-4055.2015.02.18

Abstract：Objective To observe the curative effect of Naoxintong Capsules combining metoprolol on coronary heart disease (CHD) complicating frequent premature ventricular contraction (FPVC).Methods The patients with CHD complicating FPVC (n=168) were chosen from Jan. 2011 to Apr. 2014, and then randomly divided into control group and observation group (eachn=84). On the base of routine treatment, control group was given metoprolol (25 mg, bid) and observation group, Naoxintong Capsules (1.6 g, tid) besides of metoprolol for 4 w. The primary observation endpoint was patients’ outcomes and FPVC amelioration, and outcomes included symptom relief and changes of heart function indexes. FPVC was reviewed through observing on number of premature ventricular contraction (PVC) with Holter. The secondary observation endpoint was heart rate variability (HRV) and adverse reactions.Results At the end of observation course, the overall effect was more significant (88.1%vs. 75%,P<0.05), LVEF increased more significantly [(51.6±3.4)%vs. (47.4±4.2)%,P<0.05], and number of PVC decreased significantly [(427±89) times/24hvs. (525±114) times/24h,P<0.05] in observation group compared with control group. The results of observing HRV showed that HRV amelioration was more significant in observation group compared with control group including SDNN [(133.5±28.4) msvs. (112.2±17.2) ms], Rmssd [(37.4±9.0) msvs. (26.8±5.8) ms)], LF [(530.6±78.0) Hzvs. (445.3±88.0) Hz] and HF [(298.3±54.5) Hzvs. (241.4±36.4) Hz, allP<0.05]. The adverse reactions were all mild and the incidence had no statistical difference between 2 groups (14.29%vs. 10.71%,P=0.484).Conclusion In patients with CHD complicating FPVC, metoprolol combining Naoxintong Capsules improves significantly heart function and corrects HRV decrease, which was well tolerated by patients, and promises prognosis compared metoprolol monotherapy,.